Extremely potent human monoclonal antibodies from convalescent Covid-19 patients
SUMMARY Human monoclonal antibodies are safe, preventive and therapeutic tools, that can be rapidly developed to help restore the massive health and economic disruption caused by the Covid-19 pandemic. By single cell sorting 4277 SARS-CoV-2 spike protein specific memory B cells from 14 Covid-19 survivors, 453 neutralizing antibodies were identified and 220 of them were expressed as IgG. Up to 65,9% of monoclonals neutralized the wild type virus at a concentration of >500 ng/mL, 23,6% neutralized the virus in the range of 100 - 500 ng/mL and 9,1% had a neutralization potency in the range of 10 - 100 ng/mL. Only 1,4% neutralized the authentic virus with a potency of 1-10 ng/mL. We found that the most potent neutralizing antibodies are extremely rare and recognize the RBD, followed in potency by antibodies that recognize the S1 domain, the S-protein trimeric structure and the S2 subunit. The three most potent monoclonal antibodies identified were able to neutralize the wild type and D614G mutant viruses with less than 10 ng/mL and are good candidates for the development of prophylactic and therapeutic tools against SARS-CoV-2.One Sentence Summary Extremely potent neutralizing human monoclonal antibodies isolated from Covid-19 convalescent patients for prophylactic and therapeutic interventions..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
bioRxiv.org - (2021) vom: 15. Dez. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Andreano, Emanuele [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1101/2020.10.07.328302 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI019081456 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI019081456 | ||
| 003 | DE-627 | ||
| 005 | 20230429092216.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201010s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.10.07.328302 |2 doi | |
| 035 | |a (DE-627)XBI019081456 | ||
| 035 | |a (biorXiv)10.1101/2020.10.07.328302 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Andreano, Emanuele |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Extremely potent human monoclonal antibodies from convalescent Covid-19 patients |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a SUMMARY Human monoclonal antibodies are safe, preventive and therapeutic tools, that can be rapidly developed to help restore the massive health and economic disruption caused by the Covid-19 pandemic. By single cell sorting 4277 SARS-CoV-2 spike protein specific memory B cells from 14 Covid-19 survivors, 453 neutralizing antibodies were identified and 220 of them were expressed as IgG. Up to 65,9% of monoclonals neutralized the wild type virus at a concentration of >500 ng/mL, 23,6% neutralized the virus in the range of 100 - 500 ng/mL and 9,1% had a neutralization potency in the range of 10 - 100 ng/mL. Only 1,4% neutralized the authentic virus with a potency of 1-10 ng/mL. We found that the most potent neutralizing antibodies are extremely rare and recognize the RBD, followed in potency by antibodies that recognize the S1 domain, the S-protein trimeric structure and the S2 subunit. The three most potent monoclonal antibodies identified were able to neutralize the wild type and D614G mutant viruses with less than 10 ng/mL and are good candidates for the development of prophylactic and therapeutic tools against SARS-CoV-2.One Sentence Summary Extremely potent neutralizing human monoclonal antibodies isolated from Covid-19 convalescent patients for prophylactic and therapeutic interventions. | ||
| 700 | 1 | |a Nicastri, Emanuele |e verfasserin |4 aut | |
| 700 | 1 | |a Paciello, Ida |e verfasserin |4 aut | |
| 700 | 1 | |a Pileri, Piero |e verfasserin |4 aut | |
| 700 | 1 | |a Manganaro, Noemi |e verfasserin |4 aut | |
| 700 | 1 | |a Piccini, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Manenti, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Pantano, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Kabanova, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Troisi, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Vacca, Fabiola |e verfasserin |4 aut | |
| 700 | 1 | |a Cardamone, Dario |e verfasserin |4 aut | |
| 700 | 1 | |a De Santi, Concetta |e verfasserin |4 aut | |
| 700 | 1 | |a Benincasa, Linda |e verfasserin |4 aut | |
| 700 | 1 | |a Agrati, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Capobianchi, Maria Rosaria |e verfasserin |4 aut | |
| 700 | 1 | |a Castilletti, Concetta |e verfasserin |4 aut | |
| 700 | 1 | |a Emiliozzi, Arianna |e verfasserin |4 aut | |
| 700 | 1 | |a Fabbiani, Massimiliano |e verfasserin |4 aut | |
| 700 | 1 | |a Montagnani, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Depau, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Brunetti, Jlenia |e verfasserin |4 aut | |
| 700 | 1 | |a Bracci, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Montomoli, Emanuele |e verfasserin |4 aut | |
| 700 | 1 | |a Sala, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Ippolito, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Rappuoli, Rino |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 15. Dez. |
| 773 | 1 | 8 | |g year:2021 |g day:15 |g month:12 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.cell.2021.02.035 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.10.07.328302 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 15 |c 12 | ||
| 953 | |2 045F |a 570 | ||